Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026)
Sera Prognostics (SERA) posted Net Income towards Common Stockholders of -$10.9 million for Q1 2026, down 117.33% on a QoQ basis from -$5.0 million in Q4 2025, and down 27.82% year-over-year from -$15.0 million in Q1 2025.
Sera Prognostics (SERA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Sera Prognostics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$10.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 27.82% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.9 million (down 17.14% YoY) and the FY2025 annual result came in at -$118.0 million, down 5.32% from the prior year.
- Net Income towards Common Stockholders was -$10.9 million for Q1 2026 at Sera Prognostics, down from -$5.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$5.0 million in Q4 2025 and bottomed at -$12.7 million in Q3 2025.
- A 5-year average of -$9.9 million and a median of -$10.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 70.51% — and 2025, when it surged 46.7%.
- Sera Prognostics' Net Income towards Common Stockholders stood at -$10.4 million in 2022, then increased by 28.09% to -$7.5 million in 2023, then declined by 24.9% to -$9.4 million in 2024, then jumped by 46.7% to -$5.0 million in 2025, then sank by 117.33% to -$10.9 million in 2026.
- Business Quant data shows SERA's Net Income towards Common Stockholders at -$10.9 million in Q1 2026, -$5.0 million in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Sera Prognostics | 105.54 Mn | 105.54 Mn | -28,000.00 | -10.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | -12.38 Mn |
| Mar 31, 2025 | -8.50 Mn |
| Dec 31, 2024 | -9.37 Mn |
| Sep 30, 2024 | -8.29 Mn |
| Jun 30, 2024 | -8.74 Mn |
| Mar 31, 2024 | -8.92 Mn |
| Dec 31, 2023 | -7.51 Mn |
| Sep 30, 2023 | -7.83 Mn |
| Jun 30, 2023 | -11.47 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.44 Mn |
| Sep 30, 2022 | -11.21 Mn |
| Jun 30, 2022 | -11.90 Mn |
| Mar 31, 2022 | -12.45 Mn |
| Dec 31, 2021 | -12.55 Mn |
| Sep 30, 2021 | -9.88 Mn |
| Jun 30, 2021 | -7.36 Mn |